Conversion From LFHS To RP Scherer Softgel Capsules

Summary: A virtual biotechnology company had successfully reached Phase II clinical trials for an innovative new chemical entity to treat an aggressive form of cancer. However, the Liquid Filled Hardshell (LFHS) dose form was presenting hurdles, limiting this much needed lifesaving treatment from progressing toward commercialization. By partnering their innovative NCE with the Catalent development expertise, the company was able to quickly progress through clinical trials and into commercialization with an overall better treatment.

Download the file